GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kaleido Biosciences Inc (OTCPK:KLDO) » Definitions » Issuance of Stock

Kaleido Biosciences (Kaleido Biosciences) Issuance of Stock : $69.93 Mil (TTM As of Dec. 2021)


View and export this data going back to 2019. Start your Free Trial

What is Kaleido Biosciences Issuance of Stock?

Kaleido Biosciences's Issuance of Stock for the three months ended in Dec. 2021 was $0.00 Mil.

Kaleido Biosciences's Issuance of Stock for the trailing twelve months (TTM) ended in Dec. 2021 was $69.93 Mil.


Kaleido Biosciences Issuance of Stock Historical Data

The historical data trend for Kaleido Biosciences's Issuance of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaleido Biosciences Issuance of Stock Chart

Kaleido Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Issuance of Stock
Get a 7-Day Free Trial - - 67.76 37.76 69.93

Kaleido Biosciences Quarterly Data
Dec16 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Issuance of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.43 69.98 -0.05 - -

Kaleido Biosciences Issuance of Stock Calculation

A company may raise cash from issuing new shares. Issuance of Stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Issuance of Stock for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $69.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kaleido Biosciences Issuance of Stock Related Terms

Thank you for viewing the detailed overview of Kaleido Biosciences's Issuance of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaleido Biosciences (Kaleido Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
65 Hayden Avenue, Lexington, MA, USA, 02421
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.
Executives
Alison S Long officer: Chief Medical Officer KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Van Hylckama Vlieg Johan officer: Chief Scientific Officer C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Daniel L Menichella director, officer: Chief Executive Officer 79 TW ALEXANDER DRIVE, 4101 RESEARCH COMMONS, RESEARCH TRIANGLE PARK NC 27709
Kyriazi Theo Melas director 2150 ST. ELZEAR BLVD. WEST, LAVAL A8 H7L 4A8
Nutritional Health Ltp Fund General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Nutritional Health Ltp Fund, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Anne Prener director C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139
William E. Duke officer: CHIEF FINANCIAL OFFICER C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807
Richard William Scalzo officer: Principal Accounting Officer 25 ALBERTA LANE, HOLLISTON MA 01746
Jean K Mixer director C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Jerald Korn officer: General Counsel 128 GORDON RD, NEWTON MA 02468
Flagship Ventures Fund V, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Michael W Bonney director, officer: Executive Chair 65 HAYDEN AVE, LEXINGTON MA 02421
Flagship Venturelabs V Manager Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142

Kaleido Biosciences (Kaleido Biosciences) Headlines

From GuruFocus

Kaleido Biosciences Reports Second Quarter 2021 Financial Results

By Marketwired Marketwired 08-11-2021

Kaleido Biosciences Reports First Quarter 2021 Financial Results

By Marketwired Marketwired 05-04-2021

Kaleido Biosciences Announces Pricing of Public Offering of Common Stock

By GlobeNewswire GlobeNewswire 02-04-2021